title: [Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma].
abstract: Transarterial chemoembolization (TACE) is the standard treatment in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). New drug eluting beads aim at improving efficacy of TACE in retaining as long as possible the anticancer drug within the tumor. Our monocentric study compares direct hospital medical costs, according to two different methods, for a first course of conventional TACE and for a first course of TACE using drug eluting beads in 30 patients with HCC. The average cost of a first course of conventional TACE valued by the analytic accounting system is 4 332 € versus 3 577 € for a first course of TACE using drug eluting beads. The average cost of a first course of conventional TACE valued by the official tariffs from the new French Diagnosis Related Group prospective payment system is 4 507 € (+175 €) versus 2 852 € (-725 €) for a first course of TACE using drug eluting beads. Our study shows that a first TACE using drug eluting beads, valued by the official tariffs from the new French Diagnosis Related Group prospective payment system, is significantly (p  =  0.006) less expensive than a first conventional TACE.
authors.affiliation: CHU Dijon, pôle pharmaceutique, France. charlotte.malbranche@chu-dijon.fr
authors.forename: Charlotte
authors.initials: C
authors.lastname: Malbranche
authors.forename: Mathieu
authors.initials: M
authors.lastname: Boulin
authors.forename: Boris
authors.initials: B
authors.lastname: Guiu
authors.forename: Corinne
authors.initials: C
authors.lastname: Pernot
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Cercueil
authors.forename: Ludwig
authors.initials: L
authors.lastname: Serge Aho
authors.forename: Angela
authors.initials: A
authors.lastname: Musat
authors.forename: Laurent
authors.initials: L
authors.lastname: Bedenne
authors.forename: Patrick
authors.initials: P
authors.lastname: Hillon
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Guignard
authors.forename: Philippe
authors.initials: P
authors.lastname: Fagnoni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D016461:Chemoembolization, Therapeutic / Q000191:economics* / Q000379:methods; D004180:Direct Service Costs; D004317:Doxorubicin / Q000008:administration & dosage; D016503:Drug Delivery Systems / Q000191:economics; D005260:Female; D005602:France; D017722:Hospital Charges; D006760:Hospitalization / Q000191:economics; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008863:Microspheres; D008875:Middle Aged
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin